Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with CPI Therapy in Metastatic Renal Cell Carcinoma
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented […]
